<DOC>
	<DOC>NCT00498667</DOC>
	<brief_summary>A retrospective analysis will be performed regarding the usefulness of PET/CT performed following 2 cycle of chemotherapy in evaluation of progression, free survival and overall survival of patients with aggressive non Hodgkin Lymphoma.</brief_summary>
	<brief_title>The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma</brief_title>
	<detailed_description>Patients who were treated for aggressive non-Hodgkin lymphoma with adriamycin containing regimen, CHOP and High dose CHOP with or without rituximab were evaluated post 2 cycles of chemotherapy to rule out disease progression . Currently a retrospective evaluation of PET/CT as a predictive value for progression free survival and overall survival is evaluated</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<criteria>aggressive nonHodgkin lymphoma b cells age 1870 bilirubin less then 2 creatinine less then 2 Pet/CT performed post 2 cycles no PET/CT post 2 cycles performed bilirubin &gt;2 creatinine more then 2 HIV positivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>PET/CT</keyword>
	<keyword>Aggressive non-Hodgkin Lymphoma</keyword>
</DOC>